Filing Overview
Adagio Therapeutics, Inc. (now associated with Invivyd, Inc.) filed a Form 8-K dated September 20, 2021. The filing furnished a corporate update and announced financial results for the quarter ended June 30, 2021 under Item 2.02.
Financial Results and Metrics
The filing text identifies the quarter-end reporting period but does not include the financial results or provide clear values for revenue, net income or loss, cash flow, margins, debt, liquidity, or other financial metrics. Those details were contained in Exhibit 99.1, the referenced press release, which is not included in the supplied text.
Material Changes Versus Prior Period
The filing text does not provide sufficient information to identify changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing states that the Company provided a corporate update, but the supplied text does not include management commentary, guidance, outlook, risk disclosures, contingencies, or unusual items from the referenced press release.
Important Investor Verification Items
- Obtain and review Exhibit 99.1 for the complete June 30, 2021 financial results and corporate update.
- Verify revenue, operating expenses, net loss, cash and cash equivalents, cash-burn rate, and liquidity runway.
- Review any disclosed clinical, regulatory, manufacturing, financing, or business-development developments and related risks.
- Confirm the company-name transition from Adagio Therapeutics, Inc. to Invivyd, Inc., as the filing identifies Adagio and the request identifies Invivyd.